Novo Nordisk Pursues Personalized Obesity Treatment Strategy

Novo Nordisk A/S is crafting a strategy to personalize obesity treatment, aiming to provide options suitable for all patient types. Ludovic Helfgott, Novo Nordisk's new Chief of Product and Portfolio Strategy, explained that the company foresees a treatment pathway that can adapt to various patient groups. He noted that this approach is currently under development and will leverage new iterations of the company's highly successful weight-loss medication, Wegovy. Part of this initiative involves plans for an oral formulation of the drug, which Novo Nordisk anticipates launching in the U.S. early next year.